Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa for Lowering Very high triglyceridEs (EVOLVE) trial

Journal of Clinical Lipidology

Volumn 8, Issue 1, 2014, Pages 94-106

  Kastelein, John J P ^a   Maki, Kevin C ^b   Susekov, Andrey ^c   Ezhov, Marat ^c   Nordestgaard, Borge G ^d   Machielse, Ben N ^e   Kling, Douglas ^e   Davidson, Michael H ^e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Biofortis Clinical Research   (United States)

^c INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^d Mental Health Services CPH   (Denmark)

^e Omthera Pharmaceuticals Inc   (United States)

Author keywords

Hypertriglyceridemia; Low density lipoprotein cholesterol; Omega 3 fatty acids; Remnants; Treatment; Triglycerides

Indexed keywords

APOLIPOPROTEIN C3; ARACHIDONIC ACID; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLIVE OIL; OMEGA 3 FATTY ACID; PHOSPHOLIPASE A2; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DYSGEUSIA; EDUCATION PROGRAM; ERUCTATION; FEMALE; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; UPPER ABDOMINAL PAIN; VOMITING; YOUNG ADULT;

HYPERTRIGLYCERIDEMIA; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA-3 FATTY ACIDS; REMNANTS; TREATMENT; TRIGLYCERIDES;

ENDPOINT DETERMINATION; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84893916503     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.10.003     Document Type: Article

References (60)

1. M. Miller, N.J. Stone, C. Ballantyne American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council of Nutrition, Physical Activity, and Metabolism; Council on Atherosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
3. M.H. Davidson, J. Johnson, M.W. Rooney, M.L. Kyle, and D.F. Kling A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study J Clin Lipidol 6 2012 573 584
4. L.D. Lawson, and B.G. Hughes Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters Biochem Biophys Res Commun 152 1988 328 335
5. L.D. Lawson, and B.G. Hughes Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal Biochem Biophys Res Commun 156 1988 960 963
6. P.M. Ridker, J.G. MacFayden, R.L. Wolfert, and W. Koenig Relationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention of patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial Clin Chem 58 2012 877 886
7. K. Musa-Veloso, M.A. Binns, and A.C. Kocenas et al. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides Nutr Rev 68 2010 155 167
8. E. Offman, T. Marenco, and S. Ferber et al. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study Vasc Health Risk Manag 9 2013 563 573
9. J. Perk, G. De Backer, H. Gohlke European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 33 2012 1635 1701
10. W.S. Harris, H.N. Ginsberg, and N. Arunakul et al. Safety and efficacy of Omacor in severe hypertriglyceridemia J Cardiovasc Risk 4 1997 385 391
11. Y. Abe, B. El-Masri, and K.T. Kimball et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion Arterioscler Thromb Vasc Biol 18 1998 723 731
12. A. Nordøy, K.H. Bønaa, H. Nilsen, R.K. Berge, J.B. Hansen, and O.C. Ingebretsen Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia J Intern Med 243 1998 163 170
13. H.J. Pownall, D. Brauchi, and C. Kilinc et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins Atherosclerosis 143 1999 285 297
14. A.F. Stalenhoef, J. de Graaf, M.E. Wittekoek, S.J. Bredie, P.N. Demacker, and J.J. Kastelein The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia Atherosclerosis 153 2000 129 138
15. S. Westphal, M. Orth, A. Ambrosch, K. Osmundsen, and C. Luley Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids Am J Clin Nutr 71 2000 914 920
16. P.N. Durrington, D. Bhatnagar, and M.I. Mackness et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin and treated patients with coronary heart disease and persisting hypertriglyceridaemia Heart 85 2001 544 548
17. D.C. Chan, G.F. Watts, T.A. Mori, P.H. Barrett, T.G. Redgrave, and L.J. Beilin Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicrons remnants in men with visceral obesity Am J Clin Nutr 77 2003 300 307
18. M.H. Davidson, E.A. Stein, H.E. Bays COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 29 2007 1354 1367
19. K.C. Maki, J.M. McKenney, M.S. Reeves, B.C. Lubin, and M.R. Dicklin Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia Am J Cardiol 102 2008 429 433
20. K.C. Maki, A.L. Lawless, and K.M. Kelley et al. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia J Cardiovasc Pharmacol 57 2011 489 494
21. K.C. Maki, A.L. Lawless, K.M. Kelley, M.R. Dicklin, A.L. Schild, and T.M. Rains Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic β-cell response in subjects with primary hypertriglyceridemia Prostaglandins Leukot Essent Fatty Acids 85 2011 143 148
22. H.E. Bays, J. McKenney, K.C. Maki, R.T. Doyle, R.N. Carter, and E. Stein Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin Mayo Clin Proc 85 2010 122 128
23. C.M. Ballantyne, H.E. Bays, and J.J. Kastelein et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study) Am J Cardiol 119 2012 984 992
24. C. Signori, C. DuBrock, and J.P. Richie et al. Administration of omega-3 fatty acids and raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial Eur J Clin Nutr 66 2012 878 884
25. I. Tatsuno, Y. Saito, K. Kudou, and J. Ootake Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study J Clin Lipidol 7 2013 199 207
26. H.E. Bays, C.M. Ballantyne, J.J. Kastelein, J.L. Isaacsohn, R.A. Braeckman, and P.N. Soni Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blInd, 12-week study with an open-label Extension [MARINE] trial) Am J Cardiol 108 2011 682 690
27. W.S. Harris n-3 Fatty acids and serum lipoproteins: human studies Am J Clin Nutr 65 1997 1645S 1654S
28. W.S. Harris, G. Lu, and G.S. Rambjør et al. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases Am J Clin Nutr 66 1997 254 260
29. J.M. McKenney, and D. Sica Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia Am J Health Syst Pharm 64 2007 595 605
30. W.S. Harris, M. Miller, A.P. Tighe, M.H. Davidson, and E.J. Schaefer Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives Atherosclerosis 197 2008 12 24
31. C.E. Tan, L. Foster, and M.J. Caslake et al. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women Arterioscler Thromb Vasc Biol 15 1995 1839 1848
32. T. Demant, and C. Packard In vivo studies of VLDL metabolism and LDL heterogeneity Eur Heart J 19 suppl H 1998 H7 H10
33. A.D. Sniderman, A. Tremblay, J. De Graaf, and P. Couture Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein J Clin Lipidol 6 2012 427 433
34. 2 mass in statin-treated subjects with hypertriglyceridemia J Clin Lipidol 5 2009 332 340
35. K.C. Maki, H.E. Bays, M.R. Dicklin, S.L. Johnson, and M. Shabbout Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia J Clin Lipidol 5 2011 483 492
36. J.G. Robinson, S. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk J Am Coll Cardiol 53 2009 316 322
37. Emerging Risk Factors Collaboration E. Di Angelantonio, P. Gao, and L. Pennells et al. Lipid-related markers and cardiovascular disease prediction JAMA 307 2012 2499 2506
38. S.M. Boekholdt, B.J. Aresenault, and S. Mora et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
39. B.M. Sondermeijer, J.S. Rana, and B.J. Arsenault et al. Non-HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study Eur J Clin Invest 43 2013 1009 1015
40. N. Yahagi, H. Shimano, and A.H. Hasty et al. A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids J Biol Chem 274 1999 35840 35844
41. D.C. Chan, G.F. Watts, P.H. Barrett, L.J. Beilin, T.G. Redgrave, and T.A. Mori Regulatory effects of HMG CoA reductase inhibitors and fish oils on Apo B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia Diabetes 51 2002 2377 2386
42. S. Khan, A.M. Minihane, and P.J. Talmud et al. Dietary long-chain n-3 PUFAs increase LDL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype J Lipid Res 43 2002 979 985
43. Y. Park, and W.S. Harris Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance J Lipid Res 44 2003 455 463
44. D.B. Jump, D. Botolin, Y. Wang, J. Xu, B. Christian, and O. Demeure Fatty acid regulation of hepatic gene transcription J Nutr 135 2005 2503 2506
45. M.H. Davidson Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids Am J Cardiol 98 2006 27i 33i
46. W.S. Harris, and D. Bulchandani Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 17 2006 387 393
47. A. Kawakami, and M. Yoshida Apolipoprotein CIII links dyslipidemia with atherosclerosis J Atheroscler Thromb 16 2009 6 11
48. O. Olivieri, N. Martinelli, and M. Sandri et al. Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and "insulin-resistant" T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction Clin Chem 51 2005 360 367
49. F.M. Sacks, P. Alaupovic, and L.A. Moye et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial Circulation 102 2000 1886 1892
50. N. Barzilai, G. Atzmon, and C. Schechter et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity JAMA 290 2003 2030 2040
51. T.I. Pollin, C.M. Damcott, and H. Shen et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection Science 322 2008 1702 1705
52. J.L. Anderson Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention Am J Cardiol 101 2008 23F 33F
53. P.P. Toth, P.A. McCullough, M.S. Wegner, and K.J. Colley Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker Exp Rev Cardiovasc Ther 8 2010 425 438
54. M.H. Davidson, C.M. Ballantyne, and T.A. Jacobson et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists J Clin Lipidol 5 2011 338 367
55. H.E. Bays, C.M. Ballantyne, R.A. Braeckman, W.G. Stirtan, and P.N. Soni Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies Am J Cardiovasc Drugs 13 2013 37 46
56. M.T. Nakamura, and T.Y. Nara Structure, function, and dietary regulation of 6, 5, and 9 desaturases Annu Rev Nutr 24 2004 345 376
57. S.K. Raatz, L.R. Young, M.J. Picklo Sr., E.R. Sauter, W. Qin, and M.S. Kurzer Total dietary fat and fatty acid content modifies plasma phospholipid fatty acids, desaturate activity indices, and urinary prostaglandin E in women Nutr Res 32 2012 1 7
58. E. Saito, T. Okada, F. Iwata, and Y. Kitamura The mechanisms mediating the effect of n-3 fatty acids on triglyceride (TG) biosynthesis in rats Prostaglandins Leukot Essent Fatty Acids 86 2012 209
59. R. DeCaterina, D. Giannessi, and A. Mazzone et al. Vascular prostacyclins is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery Circulation 82 1990 428 438
60. J.V. Patel, I. Tracey, E.A. Hughes, and G.Y. Lip Omega-3 polyunsaturated acids and cardiovascular disease: notable ethnic differences of unfulfilled promise? J Thromb Haemost 8 2010 2095 2104